课题基金 / 基金详情

ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL

ACTG 338--PHASE II ROLLING ARM MASTER PROTOCOL(PRAM) OF NOVEL ANTIRETROVIRAL
ACTG 338--新型抗逆转录病毒药物第二阶段滚臂主方案（PRAM）
批准号：
6309811
负责人：
Peter James Krause
金额：
$1.91万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6309811
关键词：
AIDS therapy adolescence (12-20) antiAIDS agent antiviral agents clinical research combination chemotherapy human subject human therapy evaluation lamivudine middle childhood (6-11) pediatric AIDS pediatric pharmacology preschool child (1-5) ritonavir stavudine zidovudine

项目摘要

项目成果

Peter James Krause的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This PRAM 1 Study will be a comparative study of the following three teatment arms: ZDV + D4T + Ritonavir vs. ZDV + 3TC + Ritonavir. Subjects enrolling in PRAM 1 must be between 24 months and 17 years of age. Children under 24 months will not be enrolled due to the lack of Phase I safety data available on the combinations of D4T + Ritonavir and ZDV + 3TC + Ritonavir. This study is now closed to enrollment. Currently one subject continues to be followed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECURRENT LYME DISEASE
RECURRENT LYME DISEASE
RECURRENT LYME DISEASE
Recurrent Lyme Disease